BUDGET IMPACT ANALYSIS OF VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB AS A TREATMENT FOR PREVIOUSLY UNTREATED LLC PATIENTS IN SPAIN

被引：0
|
作者：
Moreno, Martinez Estela [1 ]
De la Serna, Torroba Javier [2 ]
Escudero, Vilaplana Vicente [3 ]
Hernandez, Rivas Jose Angel [4 ]
Sanchez, Cuervo Marina [5 ]
Sanchez, Hernandez Raquel [6 ]
机构：
[1] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[2] Hosp 12 Octubre, Madrid, Spain
[3] Hosp Univ Gregorio Maranon, Madrid, Spain
[4] Hosp Infanta Leonor, Madrid, Spain
[5] Hosp Ramon & Cajal, Madrid, Spain
[6] Abbvie Spain SLU, Madrid, Spain
来源：
HAEMATOLOGICA | 2020年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO-128
引用
收藏
页码：214 / 214
页数：1
相关论文
共 50 条
  • [1] EFFICACY OF VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN THE TREATMENT OF PREVIOUSLY UNTREATED PATIENTS WITH LLC IN SPAIN
    Moreno, Martinez Estela
    De la Serna, Torroba Javier
    Escudero, Vilaplana Vicente
    Hernandez, Rivas Jose Angel
    Sanchez, Cuervo Marina
    Sanchez, Hernandez Raquel
    HAEMATOLOGICA, 2020, 105 : 221 - 221
  • [2] Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States
    Cho, Sang Kyu
    Manzoor, Beenish S.
    Sail, Kavita R.
    Parise, Helene
    Ravelo, Arliene
    Shapouri, Sheila
    Kapustyan, Tatyana
    Sharmokh, Simon
    Virabhak, Suchin
    Davids, Matthew S.
    Johnson, Scott
    PHARMACOECONOMICS, 2020, 38 (09) : 941 - 951
  • [3] Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States
    Sang Kyu Cho
    Beenish S. Manzoor
    Kavita R. Sail
    Hélène Parisé
    Arliene Ravelo
    Sheila Shapouri
    Tatyana Kapustyan
    Simon Sharmokh
    Suchin Virabhak
    Matthew S. Davids
    Scott Johnson
    PharmacoEconomics, 2020, 38 : 941 - 951
  • [4] A Phase II Trial of the Combination of Obinutuzumab, Venetoclax, and Ibrutinib in Patients with Previously Untreated Follicular Lymphoma
    Othman, Tamer
    Rosenberg, Aaron S.
    Timmerman, John
    Heyman, Benjamin
    Abdulhaq, Haifaa
    Tuscano, Joseph M.
    BLOOD, 2022, 140 : 11954 - 11955
  • [5] SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma
    Stathis, Anastasios
    Mey, Ulrich
    Schar, Sami
    Hitz, Felicitas
    Pott, Christiane
    Mach, Nicolas
    Krasniqi, Fatime
    Novak, Urban
    Schmidt, Christian
    Hohloch, Karin
    Kienle, Dirk Lars
    Hess, Dagmar
    Moccia, Alden A.
    Unterhalt, Michael
    Eckhardt, Katrin
    Hayoz, Stefanie
    Forestieri, Gabriela
    Rossi, Davide
    Dirnhofer, Stefan
    Ceriani, Luca
    Sartori, Giulio
    Bertoni, Francesco
    Buske, Christian
    Zucca, Emanuele
    Hiddemann, Wolfgang
    BLOOD ADVANCES, 2022, 6 (13) : 3911 - 3920
  • [6] Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia
    Hill, Brian T.
    Kalaycio, Matt
    ONCOTARGETS AND THERAPY, 2015, 8 : 2391 - 2397
  • [7] Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab and Bendamustine in Patients with Previously Untreated Follicular Lymphoma: An Interim Analysis
    Younes, Anas
    John, Burke M.
    Diefenbach, Catherine S.
    Ferrari, Silvia
    Kahn, Cyrus
    Sharman, Jeffrey P.
    Tani, Monica
    Ujjani, Chaitra S.
    Vitolo, Umberto
    Yuen, Sam
    Woodard, Paul
    Mundt, Kirsten
    Fingerle-Rowson, Gunter
    Chitra, Surya
    Sellam, Gila
    Morariu-Zamfir, Rodica
    Gilbertson, Michael
    BLOOD, 2017, 130
  • [8] SAKK 35/15: A phase I trial of obinutuzumab with venetoclax in previously untreated follicular lymphoma patients
    Stathis, A.
    Mey, U.
    Mach, N.
    Krasniqi, F.
    Hitz, F.
    Hohloch, K.
    Bertoni, F.
    Rondeau, S.
    Vilei, S. Berardi
    Eckhardt, K.
    Zucca, E.
    SWISS MEDICAL WEEKLY, 2018, 148 : 2S - 3S
  • [9] COST-MINIMIZATION AND BUDGET IMPACT ANALYSIS OF VENETOCLAX PLUS OBINUTUZUMAB VERSUS IBRUTINIB IN PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM
    Vieira, F. M.
    Ribeiro, G. N.
    Brito Filho, C.
    Travassos, A.
    VALUE IN HEALTH, 2021, 24 : S39 - S39
  • [10] Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective
    Owen, Carolyn J.
    Stewart, Douglas A.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2015, 6 (04) : 161 - 170
12345